Paraoxonase-1 Status in Patients with Hereditary Hemochromatosis

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2013 Mar 9

PMID 23471031

Citations 14

Authors

Nicola Martinelli

Anabel Garcia-Heredia

Helena Roca

Nuria Aranda

Victoria Arija

Bharti Mackness

Michael Mackness

Fabiana Busti

Gerard Aragones

Juan Pedro-Botet

Federica Pedica

Ivana Cataldo

Judit Marsillach

Jorge Joven

Domenico Girelli

Jordi Camps

Affiliations

Soon will be listed here.

Abstract

Hereditary hemochromatosis (HH) is characterized by accumulation of iron, oxidative stress, inflammation, and fibrogenesis in liver tissue. In this setting, research on the protection afforded by intracellular antioxidants is of clinical relevance. Paraoxonase-1 (PON1) is an enzyme that degrades lipid peroxides. This study investigates the alterations in serum PON1 status, PON1 gene polymorphisms, and PON1 hepatic expression in patients with HH. We performed a case-control study in 77 patients with HH (80.5% men, 22-70 years of age) and 408 healthy individuals (43.1% men, 26-74 years of age). Serum PON1 activities against different substrates and PON1192 and PON155 polymorphisms were analyzed. PON1 protein expression was investigated in 20 liver biopsies. HH patients had significantly lower serum PON1 activity, which was inversely correlated with ferritin (marker of iron stores) and serum 8-isoprostane concentrations (index of oxidative stress). PON1 protein expression in liver tissue was higher in patients and showed stronger staining in hepatocytes surrounding the areas of inflammation. Our study provides preliminary evidence that PON1 may play a role in protecting against iron-induced oxidative stress in hereditary hemochromatosis.

Citing Articles

Molecular Structure of Paraoxonase-1 and Its Modifications in Relation to Enzyme Activity and Biological Functions-A Comprehensive Review.

Lewon-Mrozek D, Kurzynoga J, Jedrzejewski P, Kedzierska K, Partyka A, Kuriata-Kordek M Int J Mol Sci. 2024; 25(23).

PMID: 39684839 PMC: 11642642. DOI: 10.3390/ijms252313129.

Serum Activities of Paraoxonase 1 (PON1) in Predicting Liver Damage Among Patients Diagnosed With Hepatocellular Carcinoma: A Case-Control Study.

Bade J, Veeramalla V, Naidu M, Lalitha D, Ponnada S, Kandi V Cureus. 2023; 15(9):e46234.

PMID: 37908943 PMC: 10613574. DOI: 10.7759/cureus.46234.

Clinical Performance of Paraoxonase-1-Related Variables and Novel Markers of Inflammation in Coronavirus Disease-19. A Machine Learning Approach.

Rodriguez-Tomas E, Iftimie S, Castane H, Baiges-Gaya G, Hernandez-Aguilera A, Gonzalez-Vinas M Antioxidants (Basel). 2021; 10(6).

PMID: 34205807 PMC: 8234277. DOI: 10.3390/antiox10060991.

A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease.

Petric B, Kunej T, Bavec A OMICS. 2020; 25(1):38-51.

PMID: 33306925 PMC: 8045895. DOI: 10.1089/omi.2020.0160.

Lactonase Activity, Status, and Genetic Variations of Paraoxonase 1 in Women with Gestational Diabetes Mellitus.

Zhou M, Liu X, Liu Q, Chen M, Bai H, Guan L J Diabetes Res. 2020; 2020:3483427.

PMID: 32090118 PMC: 7023839. DOI: 10.1155/2020/3483427.

References

Weiss G . Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat Rev Gastroenterol Hepatol. 2009; 7(1):50-8. DOI: 10.1038/nrgastro.2009.201. View

Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F . Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res. 2011; 2012:231502. PMC: 3179885. DOI: 10.1155/2012/231502. View

Marsillach J, Aragones G, Mackness B, Mackness M, Rull A, Beltran-Debon R . Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis. 2010; 9:46. PMC: 2877049. DOI: 10.1186/1476-511X-9-46. View

Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih D . Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011; 121(7):2693-708. PMC: 3223817. DOI: 10.1172/JCI42946. View

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M . Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8):1844-50. DOI: 10.2337/diabetes.50.8.1844. View

Mackness B, Mackness M, Arrol S, Turkie W, Durrington P . Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998; 423(1):57-60. DOI: 10.1016/s0014-5793(98)00064-7. View

Aranda N, Viteri F, Montserrat C, Arija V . Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Ann Hematol. 2010; 89(8):767-73. PMC: 2887936. DOI: 10.1007/s00277-010-0901-9. View

Aranda N, Viteri F, Fernandez-Ballart J, Murphy M, Arija V . Frequency of the hemochromatosis gene (HFE) 282C-->Y, 63H-->D, and 65S-->C mutations in a general Mediterranean population from Tarragona, Spain. Ann Hematol. 2006; 86(1):17-21. DOI: 10.1007/s00277-006-0179-0. View

Parra S, Marsillach J, Aragones G, Beltran R, Montero M, Coll B . Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis. 2010; 201(4):627-34. DOI: 10.1086/650312. View

10.

Thellin O, Zorzi W, Lakaye B, de Borman B, Coumans B, Hennen G . Housekeeping genes as internal standards: use and limits. J Biotechnol. 2000; 75(2-3):291-5. DOI: 10.1016/s0168-1656(99)00163-7. View

11.

Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J . Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol. 2010; 660:5-18. DOI: 10.1007/978-1-60761-350-3_2. View

12.

Kang H, Linton J, Shim J . Serum ferritin level is associated with the prevalence of metabolic syndrome in Korean adults: the 2007-2008 Korean National Health and Nutrition Examination Survey. Clin Chim Acta. 2012; 413(5-6):636-41. DOI: 10.1016/j.cca.2011.12.011. View

13.

Fang D, Fan C, Ji Q, Qi B, Li J, Wang L . Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies. Mol Biol Rep. 2012; 39(6):6801-9. DOI: 10.1007/s11033-012-1505-3. View

14.

Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R . Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004; 11(5):412-9. DOI: 10.1038/nsmb767. View

15.

Eckerson H, Wyte C, La Du B . The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983; 35(6):1126-38. PMC: 1685985. View

16.

Singh B, Arora S, Agrawal P, Gupta S . Hepcidin: a novel peptide hormone regulating iron metabolism. Clin Chim Acta. 2011; 412(11-12):823-30. DOI: 10.1016/j.cca.2011.02.014. View

17.

Stevens R, Morris J, Cordis G, Anderson L, Rosenberg D, Sasser L . Oxidative damage in colon and mammary tissue of the HFE-knockout mouse. Free Radic Biol Med. 2003; 34(9):1212-6. DOI: 10.1016/s0891-5849(03)00072-8. View

18.

James R, Deakin S . The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004; 37(12):1986-94. DOI: 10.1016/j.freeradbiomed.2004.08.012. View

19.

Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L . Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48(2):261-8. View

20.

Pietrangelo A . Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010; 139(2):393-408, 408.e1-2. DOI: 10.1053/j.gastro.2010.06.013. View